Synapse - Chung-Han Lee

Search Within

Chung-Han Lee

Results (157)

Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)

Meeting Abstract

Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Sarrio, R. G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC)

Meeting Abstract

Lee, C. H.; Wan, Y.; Smith, A. D.; Xie, R.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Kluger, H. M.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M. A.; Castonguay, V.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses

Meeting Abstract

Lee, C. H.; Shah, A. Y.; Hsieh, J. J.; Rao, A.; Pinto, A.; Bilen, M. A.; Cohn, A. L.; Di Simone, C.; Shaffer, D. R.; Girones Sarrio, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)

Meeting Abstract

Lee, C. H.; Adachi, Y.; Ikezawa, H.; Li, S. D.; Funahashi, Y.; Minoshima, Y.; Kubiak, P.; Perini, R.; Ren, M.; Smith, A. D.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Journal Article

Ged, Y.; Chaim, J. L.; DiNatale, R. G.; Knezevic, A.; Kotecha, R. R.; Carlo, M. I.; Lee, C. H.; Foster, A.; Feldman, D. R.; Teo, M. Y.; more...
Journal for ImmunoTherapy of Cancer (2020)

Fulltext@MSK | Save

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Journal Article

Ged, Y.; Gupta, R.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
BMC Urology (2020)

Fulltext@MSK | Save

Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy

Meeting Abstract

Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract

Meeting Abstract

Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save